Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape

EP: 1.Biomarkers and Molecular/ Genomic Testing in Genitourinary Cancers

EP: 2.Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023

Now Viewing

EP: 3.Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape

EP: 4.ESMO 2023 Insights: SunRISe-1 Study of TAR-200 in BCG-Unresponsive Bladder Cancer

EP: 5.Key Highlights from EV-302 Study at ESMO 2023

EP: 6.LITESPARK-003 Trial Insights: Updates from ESMO 2023

EP: 7.Future Opportunities in Genitourinary Cancers

This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.

Daneshmand discusses treatment options for BCG-unresponsive non–muscle invasive bladder cancer. Though radical cystectomy cures most patients, it has high morbidity/mortality risks, especially in elderly patients. Alternatives are needed.

If a clinical trial is unavailable or unwanted, options include doublet chemotherapy with gemcitabine plus docetaxel chemotherapy or pembrolizumab immunotherapy. Retrospective data shows 50% 2-year recurrence-free survival with gemcitabine/docetaxel. Pembrolizumab has 25% to 40% response rates.

Valrubicin, the first FDA-approved drug in this setting, has a poor 10% to 15% 1-year recurrence-free survival. More recent options include nadofaragene firadenovec. the first intravesical gene therapy (once every 3 months) with 25% to 40% 1-year recurrence-free survival.

Daneshmand notes clinical trials remain the preferred option, but new FDA-approved treatments provide alternatives for BCG-unresponsive patients. He is excited about the increasing options for this patient population.

Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.